Product Description
Overall, the global chronic total occlusion (CTO) device market was valued at $225 million in 2023. This is expected to increase over the forecast period at a CAGR of 2.2% to reach $262 million.
Throughout this medical market research, we analyzed over 10 CTO companies across 7 continents and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. The full report suite on the global market for CTO devices extends its projections up to the year 2030, thereby providing a comprehensive and anticipatory understanding of the market trends and trajectories for the given period.
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2030, and Historical Data to 2020
- Market Drivers & Limiters for Each Segment
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- COVID19 Impact
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
Global CTO Device Market Insights
A growing pattern in the market for CTO devices involves a heightened focus on advanced guidewire and microcatheter technologies. These technologies aim to improve the ability to navigate and cross challenging lesions successfully. These advancements are contributing to higher success rates in medical procedures and lowering the risk for patients.
Global CTO Device Market Share Insights
- In the past five years, Medtronic‘s role in the CTO device sector has transformed significantly. Initially marketing the Pioneer Plus® re-entry catheter range, Medtronic shifted focus after its acquisition by Volcano Corporation in August 2013. With the subsequent acquisition of Covidien in January 2015, Medtronic is currently promoting the Enteer™ Re-entry System and the Viance™ Crossing Catheter in the CTO device market.
- Cardinal Health strategically claimed the top spot in the European CTO market in 2015 through the acquisition of Johnson & Johnson’s Cordis business. With approximately half of the market share, they excel by bundling CTO products with other endovascular offerings.
- Becton Dickinson made significant moves in the CTO device market by acquiring FlowCardia in 2012. With FDA approval in 2007 and a 2011 indication for atherectomy procedures, the company distinguished its product. This strategic move positioned Becton Dickinson as a notable player, especially in a market where physicians lack reimbursements for CTO device usage.
Market Segmentation Summary
- Re-Entry Device Market
- Recanalization Device Market
Global Research Scope Summary
Report Attribute | Details |
---|---|
Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
Base Year | 2023 |
Forecast | 2024-2030 |
Historical Data | 2020-2023 |
Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
Qualitative Coverage | COVID19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.